title: Universal predictive criteria for neonatal overt thyrotoxicosis requiring treatment.
abstract: The universal predictive criteria for neonatal overt thyrotoxicosis requiring treatment were examined in 108 neonates (including a pair of twins) born to mothers with Graves' disease (36 patients under treatment with antithyroid drugs [group A] and 71 in remission [group B]). Anti-thyroid-stimulating hormone (TSH) receptor antibody activity was measured by both radioreceptor assay (TSH-binding inhibitor immunoglobulin [TBII]) and biologic stimulation assay (thyroid stimulating antibody [TSAb]). For generalization of the predictive criteria, the expression of TBII activity was standardized using standard serum made taking units of Medical Research Council long-acting thyroid stimulator, standard B as a reference, and expression of TSAb activity was standardized using bovine TSH as a standard. TBII activity was positive in 22 mothers at delivery, and TSAb activity was positive in 18. In 12 cases, both activities were positive. Both the TBII and the TSAb activity of maternal serum at delivery correlated well with that of the cord serum. Neonatal thyrotoxicosis occurred in 9 of 108 neonates (8%), of whom five (5%) had clinical overt symptoms requiring antithyroid drug treatment. In all nine cases the TBII and TSAb activities were both positive, but no neonate without TBII or TSAb activity developed thyrotoxicosis. The prediction rate (42%) of neonatal overt thyrotoxicosis was higher when both TBII and TSAb were measured than when only TBII (23%) or TSAb (28%) was measured. Clinical overt thyrotoxicosis could be predicted in five of six neonates (83%) of mothers when the cutoff levels of antibody activities were increased to a TBII activity of above 8 U/ml and TSAb activity of above 1.0 TSH microUEq.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000906:Antibodies / Q000502:physiology; D013956:Antithyroid Agents / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000502:physiology; D006111:Graves Disease / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn / Q000502:physiology; D011247:Pregnancy; D011248:Pregnancy Complications; D011989:Receptors, Thyrotropin / Q000276:immunology; D013961:Thyroid Gland / Q000187:drug effects / Q000503:physiopathology; D013971:Thyrotoxicosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology
chemical_list: D000906:Antibodies; D013956:Antithyroid Agents; D011989:Receptors, Thyrotropin